[1] Pan D. The hippo signaling pathway in development and cancer[J]. Dev Cell, 2010, 19(4): 491-505.
[2] Hong W, Guan KL. The YAP and TAZ transcription coactivators: key downstream effectors of the mammalian Hippo pathway[J]. Semin Cell Dev Biol, 2012, 23(7): 785-793.
[3] Pan D.Hippo signaling in organ size control[J]. Genes Dev, 2007, 21(8): 886-897.
[4] Zhao B, Lei QY, Guan KL. The HippoYAP pathway: new connections between regulation of organ size and cancer[J]. Curr Opin Cell Biol, 2008, 20(6): 638-646.
[5] Xu MZ, Tao TJ, Lee NP, et al. Yesassociated protein is an independent prognostic marker in hepatocellular carcinoma[J]. Cancer, 2009, 115(19): 4576-4585.
[6] Wang Y, Dong Q, Zhang Q, et al. Overexpression of yesassociated protein contributes to progression and poor prognosis of nonsmallcell lung cancer[J]. Cancer Sci, 2010, 101(5): 1279-1285.
[7] Yuan M, Tomlinson V, Lara R, et al. Yesassociated protein (YAP) functions as a tumor suppressor in breast[J]. Cell Death Differ, 2008, 15(11): 1752-1759.
[8] Zhang X, George J, Deb S, et al. The Hippo pathway transcriptional coactivator, YAP, is an ovarian cancer oncogene[J]. Oncogene, 2011, 30(25): 2810-2822.
[9] Danovi SA, Rossi M, Gudmundsdottir K, et al. Yesassociated protein (YAP) is a critical mediator of cJundependent apoptosis[J]. Cell Death Differ, 2008, 15(1): 217-219.
[10] Brent A, Bai H, Jain D, et al. Yesassociated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth[J]. J Neuropathol Exp Neurol, 2011, 70(7): 568-577. |